Cargando…

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report

Gliosarcoma is a rare malignant neoplasm. It accounts for approximately 2% of all glioblastomas. To date, there is no established treatment method for gliosarcoma, and a variety of therapies, such as surgical resection, radiotherapy, and chemotherapy, are typically employed. Here, we describe a pati...

Descripción completa

Detalles Bibliográficos
Autores principales: NAKAGAKI, Yuki, KAI, Keitaro, KOMOHARA, Yoshihiro, TAKEZAKI, Tatsuya, KURODA, Junichiro, SHINOJIMA, Naoki, SHIMOMURA, Mari, KAWAKAMI, Fumi, MIKAMI, Yoshiki, MUKASA, Akitake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japan Neurosurgical Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484818/
https://www.ncbi.nlm.nih.gov/pubmed/36186622
http://dx.doi.org/10.2176/jns-nmc.2022-0075
_version_ 1784791954138071040
author NAKAGAKI, Yuki
KAI, Keitaro
KOMOHARA, Yoshihiro
TAKEZAKI, Tatsuya
KURODA, Junichiro
SHINOJIMA, Naoki
SHIMOMURA, Mari
KAWAKAMI, Fumi
MIKAMI, Yoshiki
MUKASA, Akitake
author_facet NAKAGAKI, Yuki
KAI, Keitaro
KOMOHARA, Yoshihiro
TAKEZAKI, Tatsuya
KURODA, Junichiro
SHINOJIMA, Naoki
SHIMOMURA, Mari
KAWAKAMI, Fumi
MIKAMI, Yoshiki
MUKASA, Akitake
author_sort NAKAGAKI, Yuki
collection PubMed
description Gliosarcoma is a rare malignant neoplasm. It accounts for approximately 2% of all glioblastomas. To date, there is no established treatment method for gliosarcoma, and a variety of therapies, such as surgical resection, radiotherapy, and chemotherapy, are typically employed. Here, we describe a patient with gliosarcoma who, despite multiple tumor metastases throughout the body, including the lungs and lymph nodes, achieved a relatively long survival due to salvage therapy with local irradiation and remarkably effective chemotherapy with low-dose ifosfamide, carboplatin, and etoposide therapy. When the patient died, we performed autopsy and confirmed the nature of the primary and metastatic tumor cells that had spread throughout the patient's body. Clinical and systemic histological studies also suggested the possibility of re-metastasis to the brain from systemic metastatic foci. Gliosarcoma appears to have characteristics similar to sarcoma as well as a higher risk of systemic metastasis. Therefore, a careful follow-up is necessary in such patients.
format Online
Article
Text
id pubmed-9484818
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japan Neurosurgical Society
record_format MEDLINE/PubMed
spelling pubmed-94848182022-10-01 Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report NAKAGAKI, Yuki KAI, Keitaro KOMOHARA, Yoshihiro TAKEZAKI, Tatsuya KURODA, Junichiro SHINOJIMA, Naoki SHIMOMURA, Mari KAWAKAMI, Fumi MIKAMI, Yoshiki MUKASA, Akitake NMC Case Rep J Case Report Gliosarcoma is a rare malignant neoplasm. It accounts for approximately 2% of all glioblastomas. To date, there is no established treatment method for gliosarcoma, and a variety of therapies, such as surgical resection, radiotherapy, and chemotherapy, are typically employed. Here, we describe a patient with gliosarcoma who, despite multiple tumor metastases throughout the body, including the lungs and lymph nodes, achieved a relatively long survival due to salvage therapy with local irradiation and remarkably effective chemotherapy with low-dose ifosfamide, carboplatin, and etoposide therapy. When the patient died, we performed autopsy and confirmed the nature of the primary and metastatic tumor cells that had spread throughout the patient's body. Clinical and systemic histological studies also suggested the possibility of re-metastasis to the brain from systemic metastatic foci. Gliosarcoma appears to have characteristics similar to sarcoma as well as a higher risk of systemic metastasis. Therefore, a careful follow-up is necessary in such patients. The Japan Neurosurgical Society 2022-08-26 /pmc/articles/PMC9484818/ /pubmed/36186622 http://dx.doi.org/10.2176/jns-nmc.2022-0075 Text en © 2022 The Japan Neurosurgical Society https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives International License.
spellingShingle Case Report
NAKAGAKI, Yuki
KAI, Keitaro
KOMOHARA, Yoshihiro
TAKEZAKI, Tatsuya
KURODA, Junichiro
SHINOJIMA, Naoki
SHIMOMURA, Mari
KAWAKAMI, Fumi
MIKAMI, Yoshiki
MUKASA, Akitake
Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
title Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
title_full Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
title_fullStr Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
title_full_unstemmed Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
title_short Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report
title_sort gliosarcoma with systemic metastasis showing favorable response to ifosfamide, carboplatin, and etoposide chemotherapy: an autopsy case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484818/
https://www.ncbi.nlm.nih.gov/pubmed/36186622
http://dx.doi.org/10.2176/jns-nmc.2022-0075
work_keys_str_mv AT nakagakiyuki gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT kaikeitaro gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT komoharayoshihiro gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT takezakitatsuya gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT kurodajunichiro gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT shinojimanaoki gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT shimomuramari gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT kawakamifumi gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT mikamiyoshiki gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport
AT mukasaakitake gliosarcomawithsystemicmetastasisshowingfavorableresponsetoifosfamidecarboplatinandetoposidechemotherapyanautopsycasereport